ClinicalTrials.gg
CompletedNCT01499095EDITION IIUpdated Mar 23, 2022Results posted

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy

A Phase 3 interventional study of Lantus (Insulin glargine) and HOE901-U300 (new formulation of insulin glargine) in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 213 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-23.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
811
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
18th of 175
811 · median 253
Started
2011
with 10 others
Phase 3
60 of 176
1 open now
Registered
96th of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 18th largest by enrollment of the 175 interventional ones that give a count, is one of 11 that started in 2011, is one of 60 in phase 3, and was the 96th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

  • To compare the efficacy of insulin glargine new formulation and Lantus in terms of change in Glycated Hemoglobin A1c (HbA1c) from baseline to endpoint (scheduled Month 6) in adult participants with type 2 diabetes mellitus

Secondary Objective:

  • To compare the efficacy of insulin glargine new formulation and Lantus in terms of occurrence of nocturnal hypoglycemia
Read the detailed description

The maximum study duration was up to approximately 58 weeks per participants, consisting of:

  • up to 2 week screening period
  • 6-month comparative efficacy and safety treatment period
  • 6-month comparative safety extension period
  • 4-week safety follow-up period in a subset of participants
  • a 3-month administration substudy period starting after completion of the 6-month study period for participants willing to in a subset of participants randomized to HOE901-U300
03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with type 2 diabetes mellitus
  • Substudy inclusion criteria:

    • Completion of the 6-month study period in main study (Visit 10)
    • Randomized and treated with insulin glargine new formulation during the 6- month treatment period (Baseline - Month 6)

Exclusion criteria

Exclusion criteria:

  • Age less than (\<) 18 years
  • \<7.0% or greater than (>) 10% at screening
  • Diabetes other than type 2 diabetes mellitus
  • Less than 6 months on basal insulin treatment together with oral antihyperglycemic drug(s) and self-monitoring of blood glucose
  • Participants using sulfonylurea in the last 2 months before screening visit
  • Any to use of insulin glargine as defined in the national product label
  • Use of insulin pump in the last 6 months before screening
  • Initiation of new glucose-lowering medications in the last 3 months before screening visit
  • History or presence of significant diabetic retinopathy or macular edema likely to require laser or injectable drugs or surgical treatment during the study period
  • Pregnant or breast-feeding women or women who intend to become pregnant during the study period
  • Substudy exclusion criteria:

    • Participant not willing to use the adaptable injection intervals on at least two days per week

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
811 participants (actual)

Study arms

  • Experimental
    HOE901-U300

    Drug: HOE901-U300 (new formulation of insulin glargine)

  • Active comparator
    Lantus

    Drug: Lantus (Insulin glargine)

Interventions

  • DrugInsulin GlargineStudies of Insulin GlargineInsulin Glargine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).

    Also known as: Lantus

  • DrugInsulin GlargineStudies of Insulin GlargineInsulin Glargine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s). Dose titration seeking fasting plasma glucose 4.4 - 5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.

06

What researchers measure

Primary outcomes

  1. Change in HbA1c From Baseline to Month 6 Endpoint

    Only measurements performed before initiation of rescue therapy were considered in the analysis.

    Time frame: Baseline, Month 6

Secondary outcomes

  1. Percentage of Participants With At Least One Severe and/or Confirmed Nocturnal Hypoglycemia From Start of Week 9 to Month 6 Endpoint

    Nocturnal hypoglycemia was hypoglycemia that occurred between 00:00 and 05:59 hours (clock time), regardless the participant was awake or woke up because of the event. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose less than or equal to (\<=) 3.9 mmol/L (70 milligram per deciliter \[mg/dL\]). Only measurements performed before initiation of rescue therapy were considered in the analysis.

    Time frame: Week 9 Up to Month 6

  2. Change in Average Preinjection Self-Monitored Plasma Glucose (SMPG) From Baseline to Month 6 Endpoint

    Preinjection SMPG was measured within 30 minutes prior to the injection of the study drug. Average was assessed by the mean of at least 3 SMPG calculated over the 7 days preceding the assessment visit. Only measurements performed before initiation of rescue therapy were considered in the analysis.

    Time frame: Baseline, Month 6

  3. Change in Variability of Preinjection SMPG From Baseline to Month 6 Endpoint

    Preinjection SMPG was measured within 30 minutes prior to the injection of the study drug. Variability was assessed by the mean of co-efficient of variation calculated as 100 multiplied by (standard deviation/mean) over at least 3 SMPG measured during the 7 days preceding the assessment visit. Only measurements performed before initiation of rescue therapy were considered in the analysis.

    Time frame: Baseline, Month 6

  4. Percentage of Participants With HbA1c <7% at Month 6 Endpoint

    Only measurements performed before initiation of rescue therapy were considered in the analysis.

    Time frame: Month 6

  5. Change in Fasting Plasma Glucose (FPG) From Baseline to Month 6 Endpoint

    Only measurements performed before initiation of rescue therapy were considered in the analysis.

    Time frame: Baseline, Month 6

  6. Percentage of Participants With FPG <5.6 mmol/L (<100 mg/dL) at Month 6 Endpoint

    Only measurements performed before initiation of rescue therapy were considered in the analysis.

    Time frame: Month 6

  7. Change in 8-Point SMPG Profiles Per Time Point From Baseline to Month 6 Endpoint

    Change in each time-point of 8-point SMPG profile: 03:00 hours (clock time) at night; before and 2 hours after breakfast; before and 2 hours after lunch; before and 2 hours after dinner; and at bedtime. Only measurements performed before initiation of rescue therapy were considered in the analysis.

    Time frame: Baseline, Month 6

  8. Change in Daily Basal Insulin Dose From Baseline to Month 6 Endpoint

    Only measurements performed before initiation of rescue therapy were considered in the analysis.

    Time frame: Baseline, Month 6

  9. Change in Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint

    DTSQ is a validated measure to assess how satisfied participants with diabetes are with their treatment and how they perceive hyper- and hypoglycemia. It consists of 8 questions which are answered on a Likert scale from 0 to 6. DTSQ treatment satisfaction score is the sum of question 1 and 4-8 scores and ranges between 0 and 36, where higher scores indicate more treatment satisfaction. Only measurements performed before initiation of rescue therapy were considered in the analysis.

    Time frame: Baseline, Month 6

  10. Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline to Month 12

    Hypoglycemia events were Severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); Documented symptomatic hypoglycemia (typical symptoms of hypoglycemia with plasma glucose level of \<=3.9 mmol/L \[70 mg/dL\]); Asymptomatic hypoglycemia (no typical symptoms of hypoglycemia but plasma glucose level \<=3.9 mmol/L); Probable symptomatic hypoglycemia (an event during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination, but was presumably caused by a plasma glucose level \<=3.9 mmol/L, symptoms treated with oral carbohydrate without a test of plasma glucose); Relative hypoglycemia (an event during which the person with diabetes reported any of the typical symptoms of hypoglycemia, and interpreted the symptoms as indicative of hypoglycemia, but plasma glucose level \>3.9 mmol/L); Severe and/or confirmed a hypoglycemia (plasma glucose \<=3.9 mmol/L).

    Time frame: Up to Month 12

Other outcomes

  1. Change in HbA1c From Month 6 to Month 9

    Substudy comparing fixed dosing regimen (every 24 hours) vs. adaptive dosing regimen (every 24 +/- 3 hours) in a subset of participants randomized to HOE901-U300 and treated for 6 months. Only measurements performed before initiation of rescue therapy were considered in the analysis.

    Time frame: Month 6 up to Month 9

07

Results

Posted Apr 23, 2015

Participant flow

A total of 1250 participants were screened, of whom 439 participants were screen failure and 811 participants were randomized.

Participant flow — Overall Study
MilestoneHOE901-U300Lantus
Started404407
Treated403406
Participated in substudy890
Modified intent-to-treat population403405
Completed315314
Not completed8993
Withdrew: Randomized but not treated11
Withdrew: Adverse event127
Withdrew: Lack of efficacy21
Withdrew: Protocol violation67
Withdrew: Received rescue therapy3240
Withdrew: Diverse reasons2225
Withdrew: Lost to follow-up64
Withdrew: Insulin dropped below authorized dose05
Withdrew: Hypoglycemia31
Withdrew: Diagnosed with type 1 diabetes mellitus21
Withdrew: Change in injection schedule20
Withdrew: Perceived lack of efficacy11

Outcome measures

PrimaryChange in HbA1c From Baseline to Month 6 Endpoint

Only measurements performed before initiation of rescue therapy were considered in the analysis.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · percentage of hemoglobin
Change in HbA1c From Baseline to Month 6 Endpoint
percentage of hemoglobinHOE901-U300Lantus
Change in HbA1c From Baseline to Month 6 Endpoint-0.57 ± 0.094-0.56 ± 0.093
Statistical analysis
  • HOE901-U300 vs Lantus · Least squares (ls) mean difference: -0.01 · 95% CI -0.139 to 0.119
SecondaryPercentage of Participants With At Least One Severe and/or Confirmed Nocturnal Hypoglycemia From Start of Week 9 to Month 6 Endpoint

Nocturnal hypoglycemia was hypoglycemia that occurred between 00:00 and 05:59 hours (clock time), regardless the participant was awake or woke up because of the event. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose less than or equal to (\<=) 3.9 mmol/L (70 milligram per deciliter \[mg/dL\]). Only measurements performed before initiation of rescue therapy were considered in the analysis.

Time frame:
Week 9 Up to Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With At Least One Severe and/or Confirmed Nocturnal Hypoglycemia From Start of Week 9 to Month 6 Endpoint
percentage of participantsHOE901-U300Lantus
Percentage of Participants With At Least One Severe and/or Confirmed Nocturnal Hypoglycemia From Start of Week 9 to Month 6 Endpoint21.627.9
Statistical analysis
  • HOE901-U300 vs Lantus · Cochran-Mantel-Haenszel · p = 0.0380 · Risk ratio (rr): 0.77 · 95% CI 0.61 to 0.99
SecondaryChange in Average Preinjection Self-Monitored Plasma Glucose (SMPG) From Baseline to Month 6 Endpoint

Preinjection SMPG was measured within 30 minutes prior to the injection of the study drug. Average was assessed by the mean of at least 3 SMPG calculated over the 7 days preceding the assessment visit. Only measurements performed before initiation of rescue therapy were considered in the analysis.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · mmol/L
Change in Average Preinjection Self-Monitored Plasma Glucose (SMPG) From Baseline to Month 6 Endpoint
mmol/LHOE901-U300Lantus
Change in Average Preinjection Self-Monitored Plasma Glucose (SMPG) From Baseline to Month 6 Endpoint-0.56 ± 0.278-0.51 ± 0.275
Statistical analysis
  • HOE901-U300 vs Lantus · ANCOVA · p = 0.8279 · Ls mean difference: -0.04 · 95% CI -0.438 to 0.350
SecondaryChange in Variability of Preinjection SMPG From Baseline to Month 6 Endpoint

Preinjection SMPG was measured within 30 minutes prior to the injection of the study drug. Variability was assessed by the mean of co-efficient of variation calculated as 100 multiplied by (standard deviation/mean) over at least 3 SMPG measured during the 7 days preceding the assessment visit. Only measurements performed before initiation of rescue therapy were considered in the analysis.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · percentage of mean
Change in Variability of Preinjection SMPG From Baseline to Month 6 Endpoint
percentage of meanHOE901-U300Lantus
Change in Variability of Preinjection SMPG From Baseline to Month 6 Endpoint-2.34 ± 1.425-0.53 ± 1.408
SecondaryPercentage of Participants With HbA1c <7% at Month 6 Endpoint

Only measurements performed before initiation of rescue therapy were considered in the analysis.

Time frame:
Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c <7% at Month 6 Endpoint
percentage of participantsHOE901-U300Lantus
Percentage of Participants With HbA1c <7% at Month 6 Endpoint30.630.4
SecondaryChange in Fasting Plasma Glucose (FPG) From Baseline to Month 6 Endpoint

Only measurements performed before initiation of rescue therapy were considered in the analysis.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · mmol/L
Change in Fasting Plasma Glucose (FPG) From Baseline to Month 6 Endpoint
mmol/LHOE901-U300Lantus
Change in Fasting Plasma Glucose (FPG) From Baseline to Month 6 Endpoint-1.03 ± 0.242-1.21 ± 0.241
SecondaryPercentage of Participants With FPG <5.6 mmol/L (<100 mg/dL) at Month 6 Endpoint

Only measurements performed before initiation of rescue therapy were considered in the analysis.

Time frame:
Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With FPG <5.6 mmol/L (<100 mg/dL) at Month 6 Endpoint
percentage of participantsHOE901-U300Lantus
Percentage of Participants With FPG <5.6 mmol/L (<100 mg/dL) at Month 6 Endpoint29.433.6
SecondaryChange in 8-Point SMPG Profiles Per Time Point From Baseline to Month 6 Endpoint

Change in each time-point of 8-point SMPG profile: 03:00 hours (clock time) at night; before and 2 hours after breakfast; before and 2 hours after lunch; before and 2 hours after dinner; and at bedtime. Only measurements performed before initiation of rescue therapy were considered in the analysis.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · mmol/L
Change in 8-Point SMPG Profiles Per Time Point From Baseline to Month 6 Endpoint
mmol/LHOE901-U300Lantus
03:00 at Night (n= 338, 328)-0.56 ± 0.323-0.90 ± 0.321
Pre-breakfast (n= 347, 338)-1.31 ± 0.221-1.81 ± 0.219
2 hours after breakfast (n= 341, 328)-1.41 ± 0.331-1.82 ± 0.329
Pre-lunch (n= 344, 332)-0.64 ± 0.300-1.12 ± 0.298
2 hours after lunch (n= 339, 328)-1.02 ± 0.342-1.04 ± 0.340
Pre-dinner (n=347, 336)-0.94 ± 0.327-0.69 ± 0.324
2 hours after dinner (n= 338, 327)-0.69 ± 0.359-1.00 ± 0.357
Bedtime (n= 325, 303)-0.99 ± 0.345-1.00 ± 0.343
SecondaryChange in Daily Basal Insulin Dose From Baseline to Month 6 Endpoint

Only measurements performed before initiation of rescue therapy were considered in the analysis.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · U/kg
Change in Daily Basal Insulin Dose From Baseline to Month 6 Endpoint
U/kgHOE901-U300Lantus
Change in Daily Basal Insulin Dose From Baseline to Month 6 Endpoint0.28 ± 0.0210.17 ± 0.021
SecondaryChange in Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint

DTSQ is a validated measure to assess how satisfied participants with diabetes are with their treatment and how they perceive hyper- and hypoglycemia. It consists of 8 questions which are answered on a Likert scale from 0 to 6. DTSQ treatment satisfaction score is the sum of question 1 and 4-8 scores and ranges between 0 and 36, where higher scores indicate more treatment satisfaction. Only measurements performed before initiation of rescue therapy were considered in the analysis.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · units on a scale
Change in Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint
units on a scaleHOE901-U300Lantus
Change in Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint3.05 ± 0.4483.61 ± 0.440
SecondaryPercentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline to Month 12

Hypoglycemia events were Severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); Documented symptomatic hypoglycemia (typical symptoms of hypoglycemia with plasma glucose level of \<=3.9 mmol/L \[70 mg/dL\]); Asymptomatic hypoglycemia (no typical symptoms of hypoglycemia but plasma glucose level \<=3.9 mmol/L); Probable symptomatic hypoglycemia (an event during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination, but was presumably caused by a plasma glucose level \<=3.9 mmol/L, symptoms treated with oral carbohydrate without a test of plasma glucose); Relative hypoglycemia (an event during which the person with diabetes reported any of the typical symptoms of hypoglycemia, and interpreted the symptoms as indicative of hypoglycemia, but plasma glucose level \>3.9 mmol/L); Severe and/or confirmed a hypoglycemia (plasma glucose \<=3.9 mmol/L).

Time frame:
Up to Month 12
Reported as:
Number · percentage of participants
Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline to Month 12
percentage of participantsHOE901-U300Lantus
Any Hypoglycemia Event: All Hypoglycemia79.983.0
Severe Hypoglycemia: All Hypoglycemia1.71.5
Documented Symptomatic: All Hypoglycemia58.863.3
Asymptomatic: All Hypoglycemia58.664.0
Probable Symptomatic: All Hypoglycemia2.73.4
Relative: All Hypoglycemia7.912.8
Severe and/or Confirmed: All Hypoglycemia78.482.0
Any Hypoglycemia Event: Nocturnal Hypoglycemia39.746.1
Severe Hypoglycemia: Nocturnal Hypoglycemia0.20.5
Documented Symptomatic: Nocturnal Hypoglycemia29.534.2
Asymptomatic: Nocturnal Hypoglycemia14.422.2
Probable Symptomatic: Nocturnal Hypoglycemia1.21.0
Relative: Nocturnal Hypoglycemia2.26.4
Severe and/or Confirmed: Nocturnal Hypoglycemia37.544.6
Other pre-specifiedChange in HbA1c From Month 6 to Month 9

Substudy comparing fixed dosing regimen (every 24 hours) vs. adaptive dosing regimen (every 24 +/- 3 hours) in a subset of participants randomized to HOE901-U300 and treated for 6 months. Only measurements performed before initiation of rescue therapy were considered in the analysis.

Time frame:
Month 6 up to Month 9
Reported as:
Least squares mean · percentage of hemoglobin
Change in HbA1c From Month 6 to Month 9
percentage of hemoglobinHOE901-U300: Adaptable Dosing IntervalsHOE901-U300: Fixed Dosing Intervals
Change in HbA1c From Month 6 to Month 9-0.12 ± 0.151-0.25 ± 0.162
Statistical analysis
  • HOE901-U300: Adaptable Dosing Intervals vs HOE901-U300: Fixed Dosing Intervals · Ls mean difference: 0.13 · 95% CI -0.152 to 0.415

Adverse events

Collected over All Adverse Events (AE) were collected from signature of informed consent form up to study completion regardless of seriousness or relationship to study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HOE901-U300—30/403 (7.4%)106/403 (26.3%)
LANTUS—30/406 (7.4%)96/406 (23.6%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventHOE901-U300LANTUS
Urinary tract infectionInfections and infestations2/4033/406
Ischaemic strokeNervous system disorders0/4033/406
Acute myocardial infarctionCardiac disorders2/4031/406
Myocardial infarctionCardiac disorders2/4030/406
Invasive lobular breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/4030/406
Angina pectorisCardiac disorders0/4032/406
PneumoniaInfections and infestations0/4032/406
Angina unstableCardiac disorders1/4030/406
Cardiac disorderCardiac disorders1/4030/406
Cardiac failureCardiac disorders1/4031/406
Most frequent other events
Most frequent other events
EventHOE901-U300LANTUS
NasopharyngitisInfections and infestations49/40331/406
Upper respiratory tract infectionInfections and infestations23/40335/406
HeadacheNervous system disorders27/40320/406
BronchitisInfections and infestations25/40323/406

Baseline characteristics

Randomized population: all screened participants (who originally met inclusion criteria and signed informed consent) allocated to a treatment group and recorded in Interactive Voice/Web Response System (IVRS/IWRS) database, regardless of whether treatment was used or not. Participants were analyzed in treatment group to which they were randomized.

Age, Continuous
Age, Continuous(years)HOE901-U300LantusTotal
Mean57.9 ± 9.158.5 ± 9.258.2 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)HOE901-U300LantusTotal
Female217222439
Male187185372
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter)HOE901-U300LantusTotal
Mean34.8 ± 6.634.8 ± 6.134.8 ± 6.4
Duration of Diabetes
Duration of Diabetes(years)HOE901-U300LantusTotal
Median11.6 (1 to 54)11.7 (1 to 51)11.7 (1 to 54)
Basal Insulin Daily Dose
Basal Insulin Daily Dose(units per kilogram)HOE901-U300LantusTotal
Mean0.660 ± 0.2210.681 ± 0.2530.671 ± 0.238
Glycated Hemoglobin A1c (HbA1c)
Glycated Hemoglobin A1c (HbA1c)(participants)HOE901-U300LantusTotal
Less Than (<) 8%144146290
Greater Than or Equal to (>=) 8%260261521
08

Study locations

213 sites
  • Investigational Site Number 840517
    Birmingham, Alabama 35213, United States
  • Investigational Site Number 840149
    Chandler, Arizona 85224, United States
  • Investigational Site Number 840093
    Glendale, Arizona 85306, United States
  • Investigational Site Number 840069
    Phoenix, Arizona 85028, United States
  • Investigational Site Number 840110
    Sun City, Arizona 85351, United States
  • Investigational Site Number 840068
    Tempe, Arizona 85282, United States
  • Investigational Site Number 840015
    Hot Springs, Arkansas 71913, United States
  • Investigational Site Number 840014
    Little Rock, Arkansas 72205, United States
  • Investigational Site Number 840114
    Little Rock, Arkansas 72205, United States
  • Investigational Site Number 840018
    Mountain Home, Arkansas 72653, United States
  • Investigational Site Number 840027
    Searcy, Arkansas 72143, United States
  • Investigational Site Number 840074
    Anaheim, California 92801, United States
  • Investigational Site Number 840509
    Bell Gardens, California 90201, United States
  • Investigational Site Number 840060
    Greenbrae, California 94904, United States
  • Investigational Site Number 840057
    La Jolla, California 92037, United States
  • Investigational Site Number 840003
    La Mesa, California 91942, United States
  • Investigational Site Number 840026
    Los Angeles, California 90073, United States
  • Investigational Site Number 840090
    Mission Hills, California 91345, United States
  • Investigational Site Number 840099
    Palm Springs, California 92262, United States
  • Investigational Site Number 840004
    San Diego, California 92161, United States
  • Investigational Site Number 840124
    Santa Barbara, California 93110, United States
  • Investigational Site Number 840012
    Tustin, California 92780, United States
  • Investigational Site Number 840104
    Colorado Springs, Colorado 80906, United States
  • Investigational Site Number 840128
    Colorado Springs, Colorado 80909, United States
  • Investigational Site Number 840098
    Denver, Colorado 80206, United States
  • Investigational Site Number 840518
    Brandon, Florida 33511, United States
  • Investigational Site Number 840049
    Daytona Beach, Florida 32117, United States
  • Investigational Site Number 840008
    Jacksonville, Florida 32258, United States
  • Investigational Site Number 840520
    Miami, Florida 33015, United States
  • Investigational Site Number 840025
    New Port Richey, Florida 34652, United States
  • Investigational Site Number 840011
    Ocoee, Florida 34761, United States
  • Investigational Site Number 840141
    Palm Harbor, Florida 34684, United States
  • Investigational Site Number 840513
    Pembroke Pines, Florida 33029, United States
  • Investigational Site Number 840528
    Columbus, Georgia 31901, United States
  • Investigational Site Number 840050
    Idaho Falls, Idaho 83404, United States
  • Investigational Site Number 840107
    Nampa, Idaho 83686, United States
  • Investigational Site Number 840199
    Chicago, Illinois 60612, United States
  • Investigational Site Number 840021
    McHenry, Illinois 60050, United States
  • Investigational Site Number 840020
    Springfield, Illinois 62704, United States
  • Investigational Site Number 840045
    Avon, Indiana 46123, United States
  • Investigational Site Number 840077
    Avon, Indiana 46123, United States
  • Investigational Site Number 840088
    Avon, Indiana 46123, United States
  • Investigational Site Number 840089
    Avon, Indiana 46123, United States
  • Investigational Site Number 840091
    Avon, Indiana 46123, United States
  • Investigational Site Number 840130
    Evansville, Indiana 47714, United States
  • Investigational Site Number 840142
    Lafayette, Indiana 47904, United States
  • Investigational Site Number 840041
    Paducah, Kentucky 42003, United States
  • Investigational Site Number 840034
    Baltimore, Maryland 21237, United States
  • Investigational Site Number 840150
    Baltimore, Maryland 21237, United States
  • Investigational Site Number 840031
    Rockville, Maryland 20852, United States
  • Investigational Site Number 840063
    Ann Arbor, Michigan 48106, United States
  • Investigational Site Number 840064
    Dearborn, Michigan 48124, United States
  • Investigational Site Number 840094
    Flint, Michigan 48504, United States
  • Investigational Site Number 840023
    Southfield, Michigan 48034, United States
  • Investigational Site Number 840066
    Eagan, Minnesota 55122, United States
  • Investigational Site Number 840081
    Minneapolis, Minnesota 55416, United States
  • Investigational Site Number 840158
    Biloxi, Mississippi 39531, United States
  • Investigational Site Number 840526
    Chesterfield, Missouri 63017, United States
  • Investigational Site Number 840502
    Butte, Montana 59701, United States
  • Investigational Site Number 840084
    Fremont, Nebraska 68025, United States
  • Investigational Site Number 840085
    Omaha, Nebraska 68130, United States
  • Investigational Site Number 840162
    Las Vegas, Nevada 89102, United States
  • Investigational Site Number 840527
    Las Vegas, Nevada 89117, United States
  • Investigational Site Number 840056
    Las Vegas, Nevada 89148, United States
  • Investigational Site Number 840135
    Summit, New Jersey 07901, United States
  • Investigational Site Number 840145
    Toms River, New Jersey 08721, United States
  • Investigational Site Number 840087
    Toms River, New Jersey 08753, United States
  • Investigational Site Number 840140
    Calabash, North Carolina 28467, United States
  • Investigational Site Number 840139
    Hickory, North Carolina 28601, United States
  • Investigational Site Number 840153
    Hickory, North Carolina 28601, United States
  • Investigational Site Number 840047
    Wilmington, North Carolina 28401, United States
  • Investigational Site Number 840024
    Winston-Salem, North Carolina 27103, United States
  • Investigational Site Number 840065
    Fargo, North Dakota 58103, United States
  • Investigational Site Number 840007
    Cincinnati, Ohio 45236, United States
  • Investigational Site Number 840097
    Columbus, Ohio 43213, United States
  • Investigational Site Number 840113
    Dayton, Ohio 45439, United States
  • Investigational Site Number 840108
    Maumee, Ohio 43537, United States
  • Investigational Site Number 840504
    Eugene, Oregon, United States
  • Investigational Site Number 840080
    Medford, Oregon 97504, United States
  • Investigational Site Number 840148
    Tipton, Pennsylvania 16684, United States
  • Investigational Site Number 840005
    Uniontown, Pennsylvania 15401, United States
  • Investigational Site Number 840076
    Greer, South Carolina 29651, United States
  • Investigational Site Number 840503
    Simpsonville, South Carolina 29681, United States
  • Investigational Site Number 840048
    Rapid City, South Dakota 57701, United States
  • Investigational Site Number 840028
    Bristol, Tennessee 37620, United States
  • Investigational Site Number 840038
    Chattanooga, Tennessee 37404, United States
  • Investigational Site Number 840042
    Knoxville, Tennessee 37912, United States
  • Investigational Site Number 840160
    Memphis, Tennessee 38119, United States
  • Investigational Site Number 840033
    Memphis, Tennessee 38125, United States
  • Investigational Site Number 840022
    Austin, Texas 78731, United States
  • Investigational Site Number 840078
    Austin, Texas 78758, United States
  • Investigational Site Number 840519
    Corpus Christi, Texas 78404, United States
  • Investigational Site Number 840001
    Dallas, Texas 75230, United States
  • Investigational Site Number 840159
    Dallas, Texas 75231, United States
  • Investigational Site Number 840115
    Dallas, Texas 75246, United States
  • Investigational Site Number 840079
    Houston, Texas 77030, United States
  • Investigational Site Number 840514
    Houston, Texas 77074, United States
  • Investigational Site Number 840525
    San Antonio, Texas 78229, United States
  • Investigational Site Number 840161
    San Antonio, Texas 78258, United States
  • Investigational Site Number 840009
    Draper, Utah 84020, United States

Showing the first 100 of 213 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Yki-Jarvinen H, Bergenstal R, Ziemen M, Wardecki M, Muehlen-Bartmer I, Boelle E, Riddle MC; EDITION 2 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014 Dec;37(12):3235-43. doi: 10.2337/dc14-0990. Epub 2014 Sep 5. PubMed 25193531 ↗
  • Yale JF, Aroda VR, Charbonnel B, Sinclair AJ, Trescoli C, Cahn A, Bigot G, Merino-Trigo A, Brulle-Wohlhueter C, Bolli GB, Ritzel R. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes. Diabetes Metab. 2020 Apr;46(2):110-118. doi: 10.1016/j.diabet.2018.10.002. Epub 2018 Oct 23. PubMed 30366067 ↗
  • Bolli GB, Wysham C, Fisher M, Chevalier S, Cali AMG, Leroy B, Riddle MC. A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen. Diabetes Obes Metab. 2019 Feb;21(2):402-407. doi: 10.1111/dom.13515. Epub 2018 Oct 2. PubMed 30160030 ↗
  • Bonadonna RC, Renard E, Cheng A, Fritsche A, Cali A, Melas-Melt L, Umpierrez GE. Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important? Diabetes Res Clin Pract. 2018 Aug;142:19-25. doi: 10.1016/j.diabres.2018.03.041. Epub 2018 Apr 9. PubMed 29649539 ↗
  • Yale JF, Pettus JH, Brito-Sanfiel M, Lavalle-Gonzalez F, Merino-Trigo A, Stella P, Chevalier S, Buzzetti R. The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3. PLoS One. 2018 Jan 25;13(1):e0190579. doi: 10.1371/journal.pone.0190579. eCollection 2018. PubMed 29370218 ↗
  • Yki-Jarvinen H, Bergenstal RM, Bolli GB, Ziemen M, Wardecki M, Muehlen-Bartmer I, Maroccia M, Riddle MC. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension. Diabetes Obes Metab. 2015 Dec;17(12):1142-9. doi: 10.1111/dom.12532. Epub 2015 Sep 14. PubMed 26172084 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Apr 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 2 years after primary completion. A results delay was requested in Apr 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2011
First posted
Dec 26, 2011
Start
Dec 2011
Primary completionActual
Apr 2013
CompletionActual
Nov 2013
Results delay requested
Apr 8, 2014
Results first posted
Apr 23, 2015
Last update
Mar 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01499095
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 26, 2011
Start date
Dec 2011
Primary completion
Apr 2013
Completion
Nov 2013
Results posted
Apr 23, 2015
Last update
Mar 23, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion